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Abstract
Introduction
Early ambulation after total hip arthroplasty predicts early discharge. Spinal anesthesia is
preferred by many practices but can delay ambulation, especially with bupivacaine.
Mepivacaine, an intermediate-acting local anesthetic, could enable earlier ambulation than
bupivacaine. We hypothesized that patients who received mepivacaine would ambulate earlier
than those who received hyperbaric or isobaric bupivacaine for primary total hip arthroplasty.
Methods
This randomized controlled trial included American Society of Anesthesiologists
physical status 1-3 patients undergoing primary total hip arthroplasty. Patients were randomized
1:1:1 to mepivacaine 52.5 mg, hyperbaric bupivacaine 11.25 mg, or isobaric bupivacaine 12.5
mg for spinal anesthesia. The primary outcome was ambulation between 3 and 3.5 hours.
Secondary outcomes included return of motor and sensory function, postoperative pain, opioid
consumption, transient neurological symptoms, urinary retention, intraoperative hypotension,
intraoperative muscle tension, same-day discharge, length of stay, and 30-day readmissions.
Results
Of 154 patients, 50 received mepivacaine, 53 received hyperbaric bupivacaine, and 51
received isobaric bupivacaine. Patient characteristics were similar among groups. For ambulation
at 3-3.5 hours, 35/50 (70.0%) of patients met this endpoint in the mepivacaine group, followed
by 20/53 (37.7%) of hyperbaric bupivacaine, and then 9/51 (17.6%) of isobaric bupivacaine
(p<0.001). Return of motor function occurred earlier with mepivacaine. Pain and opioid
consumption were higher for mepivacaine patients in the early postoperative period only. For
ambulatory status, 23/50 (46.0%) of mepivacaine, 13/53 (24.5%) of hyperbaric bupivacaine, and
11/51 (21.5%) of isobaric bupivacaine patients had same-day discharge (p=0.014). Length of
stay was shortest in mepivacaine patients. There were no differences in transient neurological
symptoms, urinary retention, hypotension, muscle tension, or dizziness.
Discussion
Mepivacaine patients ambulated earlier and were more likely to be discharged the same
day than both hyperbaric bupivacaine and isobaric bupivacaine patients. Mepivacaine could be
beneficial for outpatient total hip arthroplasty candidates if spinal is the preferred anesthesia
type.
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Introduction
The annual volume of total hip arthroplasties in the United States could increase to
572,000 by the year 2030.1 Over the past decade, orthopaedic surgeons have focused on
programs which enable patients to recover from surgery not only safely and rapidly, but also
increasingly as outpatients.2,3 Hip arthroplasty is typically performed under general anesthesia or
spinal anesthesia. Compared to general anesthesia, spinal anesthesia reduces operative time,
complications, and blood transfusions.4 Furthermore, neuraxial anesthesia is strongly
recommended by a recent international consensus group.5
Despite these benefits, spinal anesthesia can potentially be a drawback for outpatient total
hip arthroplasty, with weakness and sensory impairment that delay ambulation and discharge.
This is especially true of bupivacaine, one of the most common medications for spinal
anesthesia. Bupivacaine is a long-acting amide local anesthetic that comes in several forms,
including hyperbaric and isobaric. Both forms produce partial motor blockade that can last 2.5-3
h with even longer sensory blockade.6,7 Alternatively, mepivacaine, an intermediate-acting amide
local anesthetic, may also be used for spinal anesthesia; it produces reliable surgical anesthesia
for 1.5-2 h8 and evidence suggests it allows for earlier ambulation after total knee arthroplasty
compared to bupivacaine.9
The primary outcome measure of this randomized, double-blind trial of total hip
arthroplasty patients was to determine the percentage of patients achieving early ambulation with
isobaric mepivacaine, hyperbaric bupivacaine, and isobaric bupivacaine. We hypothesized that
patients would ambulate earlier with mepivacaine followed by hyperbaric bupivacaine, and
finally isobaric bupivacaine.

6

Methods
General Procedures
This study was approved by the Institutional Review Board of Thomas Jefferson
University and took place at two locations (Thomas Jefferson University Hospital and Rothman
Orthopedic Specialty Hospital) from May to November 2019 and was registered at
ClinicalTrials.gov prior to patient enrollment (NCT03948386; Eric Schwenk, principle
investigator) on May 8, 2019. The full trial protocol is available by request. All participants
provided written informed consent prior to participation. This study was conducted according to
the Consolidated Standards of Reporting Trials statement.10 Retrospective institutional
performance improvement data demonstrated that the three participating surgeons routinely
completed primary total hip arthroplasty in approximately 60 minutes, thus ensuring that a shortacting spinal would be adequate for surgery. There were 10 participating anesthesiologists.
Inclusion criteria included American Society of Anesthesiologists (ASA) physical status 1-3
patients under the age of 85 years undergoing primary elective total hip arthroplasty with a
participating surgeon. All patients could walk 10 feet independently without human assistance.
Exclusion criteria included contraindication to spinal anesthesia, neuropathy in buttocks or
posterior thighs, taking more than oxycodone 30 mg by mouth daily or the equivalent, and
intolerance to a study drug. The unadjusted Charlson Comorbidity Index11 was determined based
on medical history. In this parallel-arm, double-blind (patients and assessors) study, the study
statistician initiated and distributed a computer-generated sequence using simple 1:1:1
randomization and patients were assigned in parallel to one of the following: mepivacaine 1.5%
(3.5 mL, 52.5 mg), hyperbaric bupivacaine 0.75% (1.5 mL, 11.25 mg) or isobaric bupivacaine
0.5% (2.5 mL, 12.5 mg). These doses were the lowest that the staff anesthesiologists would use
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for total hip arthroplasty and represent a reduction from the most common bupivacaine dose used
for spinal anesthesia in one review.7 Patients 74” or greater height or with body mass index 35
kg/m2 or greater were given an extra 0.5 mL of local anesthetic. The group assignment was given
to the intraoperative anesthesia team verbally by a study team member who did not participate in
postoperative assessments. Patient assignments were posted online and were only accessible by
study team members. The intraoperative anesthesia team was not blinded to the group
assignment, but patients, surgeons, and assessors were blinded. All patients received standard
preoperative multimodal analgesia, consisting of gabapentin/pregabalin and acetaminophen and
either preoperative celecoxib or intraoperative ketorolac.

Intraoperative Management
After application of blood pressure and pulse oximetry, patients received premedication
with midazolam and spinals were performed in the sitting position under sterile conditions in the
lumbar region and patients were placed in supine position after approximately 1 minute for
mepivacaine and hyperbaric bupivacaine groups and 3-4 minutes for isobaric bupivacaine.
Sensation was tested every 2-3 minutes using a blunt-tip needle, and adequate anesthesia was
confirmed when a T10 dermatomal level was achieved. If T10 was not achieved or patients had
significant motor function after 15 minutes, general anesthesia was induced. Standard ASA
monitors were used intraoperatively. For intraoperative sedation patients were given a propofol
infusion, titrated to effect by the team. Tranexamic acid 1 g was given intravenously to all
patients prophylactically and dexamethasone 4-8 mg was given for analgesia and postoperative
nausea and vomiting prophylaxis. Blood pressure was managed at the discretion of the
intraoperative anesthesia team. All surgeries were performed by three board-certified,
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fellowship-trained joint replacement surgeons with extensive experience in performing total hip
arthroplasty; two surgeons used the direct anterior approach (W.J.H. and S.A.B.) while the other
used the direct lateral approach (M.S.A.) Both surgical approaches were performed with the
patient in the supine position.
All patients were ordered intravenous fentanyl as needed in the post-anesthesia care unit
(PACU). Oxycodone or hydrocodone/acetaminophen was provided as needed once liquids were
tolerated by mouth. PACU nurses were blinded.

Primary Outcome and Physical Therapist Assessment
The primary outcome was the percentage of patients who could ambulate between 3 and
3.5 h after spinal placement. This time was chosen because of a previous study that reported
mean time to ambulation after mepivacaine spinal anesthesia at 212 minutes.8 Physical
therapists, who were blinded to group assignments, were informed of the time of spinal
placement by an investigator and then assessed patients for ambulation between 3 and 3.5 h and
then every 2 hours after that if ambulation did not occur at the previous assessment. Assessments
occurred in the PACU or on general medical/surgical floors. Physical therapists recorded the
initial Tinetti score at the time of first ambulation and total distance ambulated. The Tinetti test is
a validated instrument to predict fall risk in elderly adults;12 both the gait and ambulation
components were used, with a maximum score of 28. All patients were given a walker to assist
with ambulation.

Secondary Outcomes
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Secondary outcomes included the following: motor function return, sensory level at time
of motor function return, initial distance ambulated, Tinetti score12 at first ambulation, urinary
retention, transient neurological symptoms, lowest intraoperative blood pressure, dizziness,
length of stay, pain, surgeon intraoperative muscle tension rating, opioid consumption up to 48 h,
and 30-day readmissions. As a weak opioid tramadol was not included in the opioid calculations;
opioids were converted to oral morphine equivalents using a conversion table.13 Sources of data
included patient interviews and the electronic medical record. For pain, opioid, transient
neurological symptoms, and patient satisfaction data collected on postoperative days 1 and 2,
phone interviews were conducted if the patient was discharged.
The muscle tension rating was a 4-point Likert scale that blinded surgeons used to rate
the perceived joint tightness intraoperatively. The scale was the following: 0=most relaxed;
1=mildly tight; 2=moderately tight; and 3=very tight. Time to return of motor function was
defined as the time when muscle strength in all three muscle groups tested was 5/5 on a 0 to 5
scale with 0=no contraction, 1=muscle flicker, 2=active movement but not against gravity,
3=active movement against gravity, 4=movement against some resistance, and 5=full strength
against resistance. Motor functions tested included thigh flexion, knee extension, and toe
dorsiflexion. The sensory dermatome level at the time of motor function return was assessed
using ice. Both assessments began 30 minutes after PACU arrival and continued every 30
minutes until motor function return. Patients who still did not have 5/5 motor strength in all three
muscle groups at 6 hours received a time of 360 minutes for analysis purposes. Consistent with
previous work,14 patients were asked the following to determine if transient neurological
symptoms were present on postoperative days 0, 1, and 2: “Do you have any back pain that you
didn’t have before surgery that goes into your buttocks, thighs, hips, or lower legs?”
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Urinary retention was defined as placement of a straight catheter or Foley catheter prior
to spontaneous urination or inability to urinate for eight hours after PACU arrival, consistent
with a previous study.15 Dizziness was determined by the physical therapist at the time of first
attempted ambulation if lightheadedness, nausea, or dizziness was reported by the patient.
Length of stay was determined using the difference between the anesthesia start time and
the discharge order time. Standard discharge criteria included safely ambulating at least 100 feet,
safely negotiating stairs specific to the home setting, ability to get in and out of bed, and ability
to perform transfers to and from a chair and a toilet. A patient’s baseline level of function and
specific home setting were factored into discharge appropriateness. All secondary outcomes were
assessed by blinded study investigators.

Statistical Analysis and Sample Size Determination
Previous studies4,5 as well as our clinical experience suggested that it would be
reasonable to assume that between 3 and 3.5 h 70% of mepivacaine, 35% of hyperbaric
bupivacaine, and 25% of isobaric bupivacaine patients would ambulate. The power analysis was
performed using one-way analysis of variance (ANOVA) with a balanced design for 3 groups.
All hypotheses were based on superiority. Using the above assumptions with alpha set to 0.05,
power at 80%, and a SD of 70%, yielding 44 patients per group for a total required sample size
of 132 patients. In anticipation of screen failures and dropouts, we requested permission from the
Institutional Review Board to enroll a maximum of 20% additional patients. After testing for
normality (Shapiro-Wilk test), data were expressed as mean ± SD and non-normally distributed
data as median [interquartile range] or mean [95% CI], as appropriate. Age, body mass index,
case duration, MAP, pain and patient satisfaction ratings, Tinetti score, distance ambulated, and
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hospital length of stay variables were analyzed using one-way ANOVA (general linear model).
Sex, ASA physical status, Charlson Comorbidity Index, surgical approach, surgeon muscle
tension rating, return of motor function, same-day discharge, urinary retention, and dizziness
were analyzed using the chi-square test or Kruskal-Wallis test, as appropriate. Binary logistic
regression was used to determine if ambulation achieved between 3 and 3.5 h post-surgery was
associated with treatment. The dependent variable “ambulation achieved between 3 and 3.5 h”
was coded as a binary variable in the complete model with the 3 treatment groups entered as the
categorical independent variable with number of iterations limited to 50. We used a binary
logistic regression to test for the potential effect that surgeons may have had on the primary
outcome and reported the p values comparing those three surgeons. All tests were nondirectional and protected tests were performed for post-hoc analyses after confirming significant
main effects. The p value was set at 0.05 for statistical significance. Statistical analyses were
performed using Systat version 13, SPSS version 25, and GraphPad Prism version 6.
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Results
Patient Characteristics, Intraoperative Outcomes, and Ambulation-Related Outcomes
A total of 159 randomization assignments were allocated but because of
miscommunication 1 was never assigned to a patient, leaving 158 patients randomized. Of these,
4 were excluded for various reasons (Figure 1), leaving 154 for primary analysis: 50 patients in
mepivacaine group, 53 in hyperbaric bupivacaine group, and 51 in isobaric bupivacaine group.
Enrollment was stopped when initial sample size plus an additional 4 patients per group was
achieved for balance. However, it was later discovered that 3 patients were given a study drug
not originally assigned because of miscommunication. In-hospital data only were analyzed for
patients lost to follow-up (Figure 1). The following data were reported for all patients: age, sex,
body mass index, ASA physical status, case duration, surgical approach, lowest intraoperative
blood pressure, ambulation between 3 and 3.5 h, and initial distance ambulated. For other
outcomes, the number of patients with available data can be seen in Tables 1-3. Demographic
data are shown in Table 1. There were no differences in age, body mass index, sex, ASA
physical status, or Charlson Comorbidity Index between the 3 groups. There were also no
statistically significant differences in surgical approach or lowest intraoperative mean arterial
pressure.
The median surgeon muscle tension ratings (0-3 scale) for hyperbaric bupivacaine,
isobaric bupivacaine, and mepivacaine were 1 (IQR 1-2), 1 (IQR 0-2), and 1 (IQR 1-2),
respectively, with more patients receiving a rating of 3 in the mepivacaine group (8/14, 57.1%)
versus 3/14 (21.4%) in the hyperbaric and isobaric bupivacaine groups. There were more patients
with a rating of 0 in the isobaric bupivacaine group (13/29, 44.8%) versus 9/29 (31.0%) in
hyperbaric bupivacaine and 7/29 (24.1%) in mepivacaine groups), but these differences were not

13

statistically significant overall (Table 1, Figure 2; p=0.354). The surgical duration was slightly
shorter with mepivacaine compared to hyperbaric and isobaric bupivacaine but the difference
between the latter two was not statistically significant (Table 1). Two patients (1 mepivacaine
and 1 hyperbaric bupivacaine) were converted to general anesthesia prior to surgical incision
because of inadequate spinal level but remained in the study for analysis. Five patients (four
hyperbaric bupivacaine and one isobaric bupivacaine) received intraoperative opioids, ranging
from 25-75 mcg of intravenous fentanyl, for hypertension or tachycardia.
For the primary outcome of ambulation between 3 and 3.5 hours, 70.0% of patients met
this endpoint with mepivacaine, followed by 37.7% with hyperbaric bupivacaine, and then
17.6% with isobaric bupivacaine (p<0.001; Figure 3). Patients who received mepivacaine were
more likely to ambulate at 3.5 h than those who received hyperbaric bupivacaine (odds ratio
3.85, 95% CI 1.69-8.8, p=0.001) or isobaric bupivacaine (odds ratio 10.8, 95% CI 4.2-27.8,
p<0.001). Patients who received hyperbaric bupivacaine were more likely to walk between 3 and
3.5 h than patients who received isobaric bupivacaine (odds ratio 2.83, 95% CI 1.14-7.0,
p=0.025). Using a binary logistic regression, we confirmed that there were no statistically
significant differences in the primary outcome attributable to a specific surgeon noted by the p
values comparing the three surgeons (1 versus 2: p=0.113; 1 versus 3: p=0.721; and 2 versus 3:
p=0.142). The mean ratio of patients ambulating between 3 and 3.5 h among the 3 surgeons was
0.35 (95% CI 0.18-0.52). Overall, patients in the mepivacaine group were more likely to be
discharged home on the day of surgery than either bupivacaine group and had a shorter length of
stay than both hyperbaric and isobaric bupivacaine patients (Table 2 and Figure 4).
There were no statistically significant differences between groups regarding distance
ambulated and initial Tinetti score (Table 2), but return of motor function occurred earlier in
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mepivacaine patients followed by hyperbaric bupivacaine and then isobaric bupivacaine (109
minutes [74 – 156] versus 123 minutes [88 – 188] versus 148 minutes [120 – 205], respectively,
p=0.049; Figure 5). The most common dermatomal sensory level was L4 in mepivacaine and
hyperbaric bupivacaine groups (33.3% and 23.6%, respectively) at the time of motor function
return, while 34.3% of isobaric bupivacaine patients had a level of L3 at that time. However, the
difference in distribution of sensory levels was not statistically significant (p=0.422).

Pain Outcomes
There were no statistically significant differences in opioid consumption at any time point
between the groups except in the PACU, where mepivacaine patients used a greater amount of
opioids than hyperbaric and isobaric bupivacaine groups (Table 3). At the final PACU pain
assessment just prior to PACU discharge, mepivacaine patients reported the highest pain levels
of the three groups but the difference was only statistically greater than the isobaric bupivacaine
group (Table 3). Transient neurological symptoms occurred in 10.0% of mepivacaine, 11.3% of
hyperbaric bupivacaine, and 3.9% of isobaric bupivacaine patients (Table 3; p=0.355).

Additional Secondary Outcomes
There were no statistically significant differences in urinary retention or dizziness among
the three groups (Table 2). One patient in the hyperbaric bupivacaine group had a Foley catheter
placed but no patients were discharged home with a Foley catheter. The other 18 patients with
urinary retention either received a straight catheterization or did not urinate until after eight hours
as per the pre-determined definition. There were no differences in patient satisfaction ratings,
which were high for all patients (Table 2). Analysis of patient records revealed that 1 patient in
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the mepivacaine group was readmitted within 30 days of surgery. This patient was an 80-yearold male who was admitted 26 days postoperatively for a urinary tract infection that was possibly
related to difficult attempted Foley catheter placement in the postoperative period. No other
readmissions occurred.
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Discussion
This study demonstrates that spinal mepivacaine allows for earlier ambulation and
discharge after total hip arthroplasty than either hyperbaric or isobaric bupivacaine. This is
encouraging for outpatient programs that prefer spinal anesthesia for its outcome benefits.16
Earlier ambulation comes with more pain in the PACU. However, overall pain was low. Because
pain and opioid consumption were not different at any other time, this pain may not have
affected functional outcomes. Mepivacaine patients experienced a wider range of pain ratings
and opioid consumption in the early postoperative period but on average both were very low and
have questionable clinical significance. The routine use of both non-steroidal anti-inflammatory
drugs (NSAIDs) and dexamethasone for all patients may have partially mitigated overall pain,
leading to a statistically significant but clinically not important difference. Early ambulation
predicts successful same-day discharge,6 which is consistent with our results. The earlier return
of motor function likely allowed patients who received mepivacaine to meet physical therapy
milestones sooner, contributing to a faster discharge. Our study improves upon previous work5
because we attempted early ambulation at a time when mepivacaine would be expected to wear
off, in contrast to that study where routine ambulation assessment occurred, which is typically
several hours later.
As the push for earlier discharge after total joint arthroplasty increases, those involved in
their perioperative care, including anesthesiologists, are searching for the optimal combination of
elements that maximize same-day discharge chances. While mepivacaine is not new and has
been used since the 1960s,17 it has been avoided at many institutions. It is possible that early
reports of an association between mepivacaine and transient neurological symptoms18,19 led to
hesitance by some anesthesiologists to use the drug. We observed that 5 out of 50 mepivacaine
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patients developed transient neurological symptoms, which is slightly higher than others who
have reported an incidence of 6.4%20 and 7.5%19 with mepivacaine in orthopedic surgery.
However, patients in all three groups experienced transient neurological symptoms, and the
differences between groups were not significant.
Operative conditions were not adversely affected by mepivacaine as suggested by the
overall lack of difference in muscle tension ratings and the very small difference in case
duration, which was actually slightly shorter with mepivacaine. For many surgeons, this
difference of 10 minutes is insignificant. It was notable, however, that surgeons perceived that
more mepivacaine patients had “tight” joints, indicated by the number of patients with a rating of
3 (0-3 scale). Our study was not powered to address this outcome. This topic deserves further
exploration as others who have studied spinal mepivacaine have not addressed this.9,14,21
Previous studies found that the incidence of hypotension does not vary between hyperbaric
bupivacaine and isobaric bupivacaine7 and our results suggest that substitution of mepivacaine
for bupivacaine does not change this. Our results are generalizable to other joint programs where
early ambulation is desirable even without same-day discharge. However, we advise caution in
applying our results to surgeons with significantly longer operative times. Pawlowski et al8
previously demonstrated that 4 mL of mepivacaine 1.5% (60 mg) will regress below T10
dermatome after 120 minutes, putting patients at risk for inadequate anesthesia and conversion to
general anesthesia. Although our study dose was slightly lower and we did not measure the time
when the sensory level regressed below T10, the fact that no patient required conversion to
general anesthesia during surgery (and only two prior to incision) suggests adequate spinal
anesthesia throughout.
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Anesthetic choice is only one component of a successful outpatient program. Appropriate
patient selection is critical to achieve favorable outcomes. One study found that women, patients
≤ 40 years, patients ≥ 60 years, those with body mass index ≤ 26 kg/m2, and higher ASA
physical status were all associated with higher failure rates of same-day discharge.22 One review
of outpatient total joint arthroplasty concluded that about 95% of included patients were
discharged on the same day as planned but pain, hypotension, and nausea were the main reasons
patients did not meet criteria.23 Although beyond the scope of our study, there are clearly patient
and surgical factors that affect same-day discharge.
One of the strengths of the study includes the early and consistent time point chosen for
the primary outcome assessment. Although Mahan et al9 found no difference in ambulation time
between mepivacaine and hyperbaric bupivacaine, their retrospective study design significantly
impacted their ability to detect a difference between drugs and, furthermore, they did not specify
nor standardize the time of first attempted ambulation. Another strength of our study is the
clinically relevant primary outcome of ambulation rather than sensory or motor function alone or
pain. Because ambulation is predictive of discharge,2 this makes our results applicable to those
desiring to implement spinal anesthesia into an outpatient total hip arthroplasty program. The
shorter length of stay and greater percentage of same-day discharges further support our choice
of primary outcome as clinically meaningful. Finally, we chose to include both hyperbaric
bupivacaine and isobaric bupivacaine in the study because of the diverse practice patterns that
occur around the world. Although this required a larger sample size, we believe the results are
even more clinically applicable because of the inclusion of both drugs.
Our study has limitations. First, a specific, early time window as the primary outcome
introduces the possibility that some differences between the groups were missed as the sensory
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level is continuously regressing in the postoperative period and it is also possible that a later time
point for assessment of primary outcome could have resulted in a smaller or no difference
between groups. However, no continuous motor function monitor exists, and, at best, very
frequent assessments can approximate the time a patient is able to ambulate. The desire for
accurate ambulation time had to be balanced with the practical concerns of study staff
availability and the associated inconvenience of ambulation in the PACU. We believe that the
pharmacokinetics of the three drugs and practical concerns were best balanced with a 30-minute
window of 3-3.5 h, which was also supported by the predicted time of first ambulation with
spinal mepivacaine reported by Pawlowski et al.8 Second, only some aspects of the
intraoperative anesthetic were standardized, including premedication, spinal technique, and the
use of propofol for sedation. Adjustment of sedation and treatment of blood pressure were at the
discretion of the anesthesia team. However, this reflects clinical practice. Third, the shorter
surgical duration for mepivacaine could have influenced our primary outcome. It is not clear
what the cause of this difference was. However, a study of isobaric bupivacaine that showed that
the mean time to regress 2 dermatomal levels was 61 minutes,24 suggesting that for patients
unable to ambulate between 3 and 3.5 hours, a difference of less than 10 minutes in surgery
would not greatly affect the primary outcome. Fourth, although standard discharge criteria were
applied to all patients, postoperative hypotension was not tracked and physical therapists used
discretion in recommending same-day discharge based on safety. Finally, a few outcomes are
imprecise. Some patients had motor function assessment gaps in PACU for staffing reasons.
Motor function data should be interpreted with caution as there were several missing data points
and some patients may have regained motor function earlier than what was reported. This
limitation did not affect our primary outcome nor any other secondary outcome but it does make
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this outcome measurement less reliable than others. Urinary retention measurements relied on
patient recollection in some cases, which could have led to event misclassification.
In conclusion, spinal mepivacaine allowed for earlier postoperative ambulation and
shorter length of stay than both hyperbaric and isobaric bupivacaine. However, between 20 and
30% of both hyperbaric and isobaric bupivacaine patients were still discharged home the same
day and patient satisfaction was high in all groups. Mepivacaine might be beneficial for
outpatient total hip arthroplasty if spinal anesthesia is the desired anesthetic.
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Figure Legends
Figure 1. CONSORT flow diagram
Figure 2. Distribution of surgeon’s intraoperative muscle tension ratings using a 0-3 scale,
where 0=most relaxed, 1=mildly tight, 2=moderately tight, and 3=very tight. Superimposed on
the graph is a smaller graph showing the mean tension rating for each group with 95%
confidence intervals.
Figure 3. Percent of total hip arthroplasty patients ambulating between 3 and 3.5 hours after
spinal anesthesia with mepivacaine, hyperbaric bupivacaine, or isobaric bupivacaine
Figure 4. Percent of patients discharged on the day of surgery (left) and length of stay (right)
after total hip arthroplasty with spinal mepivacaine, hyperbaric bupivacaine, or isobaric
bupivacaine
Figure 5. Return of motor function after total hip arthroplasty under spinal anesthesia with
mepivacaine, hyperbaric bupivacaine, and isobaric bupivacaine

